Process for the preparation of N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide

US9518058B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Martin D. Eastgate · Titusville, US
• Gregory L. Beutner · Green Brook, US
• Benjamin M. Cohen · Cranford, US
• Nicolas Cuniere · Montgomery, US
• Lopa V. Desai · Chesterfield, US
• Monica Fitzgerald · Edison, US
• Qi Gao · Shanghai, CN
• Michael Bryan Hay · Scotch Plains, US
• Michael Joseph Lawler · Waunakee, US
• Paul Lobben · Lawrenceville, US
• Christopher S. Regens · San Francisco, US
• Thorsten Rosner · Berkeley Heights, US
• Neil A. Strotman · Flemington, US
• Carolyn S. Wei · Hoboken, US
• Yi Xiao · Fanwood, US
• Bin Zheng · Kendall Park, US
• Keming Zhu · Highland Park, US

Key dates

• Filing date: Aug 28, 2014
• Grant date: Dec 13, 2016
• Expiry date: Aug 28, 2034

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D403/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to an improved process for synthesizing N,N-dicyclopropyl-4-(1,5-dimethyl-1H-pyrazol-3-ylamino)-6-ethyl-1-methyl-1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide of the formula: (I) Compound (I) is currently in clinical trials for the treatment of myeloproliferative disorders, such as polycythaemia vera, thrombocythaemia and primary myelofibrosis.